Antisense and RNAi Therapeutics Market Expect $18.43 Billion By 2032, CAGR: 17.8%

Antisense and RNAi Therapeutics Market Size Worth $18.43 Billion By 2032 | CAGR: 17.8%

The global antisense and RNAi therapeutics market size is expected to reach USD 18.43 billion by 2032, according to a new study by Polaris Market Research. The report “Antisense and RNAi Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Technology (Antisense RNA and RNA Interference); By Route of Administration; By Application; By Region; Segment Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The global market for antisense and RNAi therapeutics has seen significant growth due to advancements in RNA-based drug development and improved understanding of disease mechanisms. These technologies are now being explored for new indications beyond their current uses, with many pipeline drugs targeting conditions with limited treatment options. Neurodegenerative disorders, such as Alzheimer's and Huntington's, are particularly challenging to treat, but emerging research suggests that RNA interference could offer new possibilities for addressing these conditions.

The expanding trend of multidisciplinary development approaches is having a substantial impact on the global market for antisense and RNAi therapies. Traditionally, preclinical and clinical research, regulatory affairs, and discovery were all conducted in distinct silos during the drug development process. Currently, nevertheless, there is a movement toward more integrated, interdisciplinary models that combine several fields of knowledge throughout the whole drug development life cycle.

 RNAi and antisense medicines, which pose special technical obstacles, are benefiting from this comprehensive, cooperative approach. These nucleic acid-based medications necessitate input from a broad range of scientific disciplines, including molecular biology, biochemistry, pharmacology, and clinical medicine, due to their very mechanism of action. These specialist skill sets can work in multidisciplinary teams to progress antisense and RNAi candidates more efficiently as a group.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below:

Untapped emerging markets offer significant growth opportunities for the global antisense and RNAi therapeutics market. Many developing countries have large numbers of patients suffering from life-threatening diseases, but they face limited or unavailable treatment options due to poor healthcare infrastructure and lack of access. Antisense and RNAi therapeutics have the potential to greatly improve patient outcomes in these countries by providing targeted treatments that are cost-effective and have fewer side effects than traditional drugs. This could expand access to essential medicines and facilitate the development of affordable new therapies for major diseases such as cancer, cardiovascular diseases, and hepatitis C, which have high mortality rates in these regions. Addressing the substantial unmet medical needs of underserved populations in these regions could be a driving force for market growth.

Antisense and RNAi Therapeutics Market Report Highlights

  • The antisense RNA segment dominated the market in 2023, driven by conducting tests on it to regulate various conditions.
  • The intrathecal injections segment led the market in 2023 and is expected to maintain its dominance due to its application in pain management and introduction of medications to fight particular infections.
  • North America holds a significant revenue share in the global antisense and RNAi therapeutics market, driven by major biopharmaceutical companies and heavy investment made by them in activities such as research and development.
  • The global key market players include Alynylam Pharmaceuticals, Inc., Arbutus Biopharma, Benitec Biopharma, Inc., GSK plc, Ionois Pharmaceuticals, Inc., Olix Pharmaceuticals, and Sanofi.

Polaris Market Research has segmented the Antisense and RNAi therapeutics market report based on technology, route of administration, application, and region:

Antisense and RNAi therapeutics, Technology Outlook (Revenue - USD Billion, 2019 - 2032)

  • Antisense RNA
  • RNA Interference
  • Others

Antisense and RNAi therapeutics, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)

  • Intrathecal Injections
  • Subcutaneous Injections
  • Intravenous Injections
  • Other Delivery Methods

Antisense and RNAi therapeutics, Application Outlook (Revenue - USD Billion, 2019 - 2032)

  • Neurodegenerative Disorders
  • Genetic Disease
  • Cancer
  • Cardiometabolic & Renal Disorders
  • Infectious Disease
  • Skin Disorders
  • Respiratory Disorders
  • Ocular Disorders

Antisense and RNAi therapeutics, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Australia
  • Rest of Asia Pacific
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Antisense and RNAi Therapeutics Market Report Scope

Report Attributes


Market size value in 2024

USD 4.95 billion

Revenue Forecast in 2032

USD 18.43 billion


17.8% from 2024 – 2032

Base year


Historical data

2019 – 2022

Forecast period

2024 – 2032

Quantitative units

Revenue in USD billion and CAGR from 2024 to 2032

Segments Covered

By Technology, By Route of Administration, By Application, By Region

Regional scope

North America, Europe, Asia Pacific, Latin America; Middle East & Africa


Report customization as per your requirements with respect to countries, regions, and segmentation.

For Specific Research Requirements

Request for Customized Report